Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Merck
Biopharmaceutical company
Company Info
Recent News
How the Merck/Moderna cancer vaccine works and possible barriers to wide use, includes gallery
How the Merck/Moderna cancer vaccine works and possible barriers to wide use, includes gallery
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck and Sarah Cannon team up for oncology trial efficiency
Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma
Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma
New study supports testing of Merck's Ebola vaccine in DRC outbreak
New study supports expanded testing of Merck's Ebola vaccine in response to the ongoing DRC outbreak.
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria — Endpoints News coverage of biopharma industry developments.
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy — Fierce Biotech coverage of biopharma industry developments.